Immunovant (NASDAQ:IMVT) versus Seer (NASDAQ:SEER) Head to Head Survey

Seer (NASDAQ:SEER) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.

Profitability

This table compares Seer and Immunovant’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seer	-484.51%	-25.88%	-23.07%
Immunovant	N/A	-81.55%	-73.09%

Insider and Institutional Ownership

75.2% of Seer shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 11.3% of Seer shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Seer has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.

Valuation & Earnings

This table compares Seer and Immunovant”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$14.17 million	7.64	-$86.60 million	($1.36)	-1.43
Immunovant	N/A	N/A	-$413.84 million	($2.84)	-9.37

Seer has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Seer and Immunovant, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	1	0	0	0	1.00
Immunovant	1	3	6	1	2.64

Immunovant has a consensus target price of $30.78, indicating a potential upside of 15.71%. Given Immunovant’s stronger consensus rating and higher possible upside, analysts clearly believe Immunovant is more favorable than Seer.

Summary

Seer beats Immunovant on 9 of the 14 factors compared between the two stocks.

About Seer

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.